<DOC>
	<DOCNO>NCT01168817</DOCNO>
	<brief_summary>This study examine efficacy safety combination treatment BAY60-4552 plus vardenafil patient erectile dysfunction , sufficiently respond therapy PDE5 ( Phosphodiesterase 5 ) inhibitor . Patients meet entry criterion , receive vardenafil alone first four week study assess effect PDE5 inhibitor therapy give alone . Patients insufficient therapeutic response vardenafil alone enter next part study , randomly assign one 3 treatment . There 1 3 chance receive either combination BAY60-4552 plus vardenafil , vardenafil alone , placebo . Neither patient treat physician know treatment give ( double-blinded design ) .This part study last four week Patients go clinic/hospital 7 visit 8 week .</brief_summary>
	<brief_title>Clinical Proof-of-concept Study Combination BAY60-4552 / Vardenafil Treatment Erectile Dysfunction Not Sufficiently Responsive Standard Therapy With PDE5 Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>Openlabel runin phase ( first four week ) : Written inform consent sign studyspecific procedure History ED ( Erectile Dysfunction ) least 6 month prior screen , define `` inability achieve maintain erection penis sufficient complete satisfactory sexual intercourse '' ; diagnosis ED confirm physician Stable , heterosexual relationship least 6 month prior screen Aged 18 64 year ( inclusive ) first screen examination History previous use least 1 market PDE5 ( Phosphodiesterase 5 ) inhibitor insufficient therapeutic efficacy despite use high approve dose Doubleblind treatment phase ( last four week ) : At least 4 attempt sexual intercourse 4 separate day openlabel runin phase use 20 mg vardenafil approximately 1 hour attempt intercourse IIEF EF ( International Index Erectile Function Erectile Function subscale ) score &lt; 17 At least 50 % attempt sexual intercourse openlabel runin phase unsuccessful Contraindication use vardenafil History prostatectomy due prostate cancer , include nervesparing technique . Concomitant use adrenergic blocker History spinal cord injury Resting hypotension , i.e . SBP ( Systolic Blood Pressure ) &lt; 100 mmHg rest Moderate / severe hypertension , i.e . SBP &gt; 170 mmHg DBP &gt; 110 mmHg rest Symptomatic orthostatic hypotension decrease SBP &gt; 20 mmHg DBP ( Diastolic Blood Pressure ) &gt; 10 mmHg subsequent change supine stand position</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Combination Drug Therapy</keyword>
	<keyword>Phosphodiesterase inhibitor</keyword>
</DOC>